2016, Number 11
Heparin treatment “can it improve perinatal outcomes?”
Language: Spanish
References: 27
Page: 717-729
PDF size: 509.51 Kb.
ABSTRACT
Objetive: The main objective of this task consists on reviewing the existing literature in which the possible benefits of the antithrombotic therapy are studied in the prevention of complications caused by the placenta in order to acquire an acceptable clinical training and in order to suggest different areas of study related to this topic in a future.Material and Method: In order to carry out this revision, a search of several studies published by Pubmed has been done. Clinical trials controlled in which it has been compared the possible benefit of the antithrombotic prenatal therapy opposite to the expectant conduct, in women with obstetric unfavorable precedents, with the aim to evaluate the prevention of complications caused by the placenta. In this revision, articles in which the effects of the heparin in techniques of assisted reproduction, abortions of repetition in the first trimester, antiphospholipid antibodies and thromboembolic venous diseases have not been included.
Results: After our research, 8 articles have been chosen with a total sample of 1178 women. Our revision shows a significant statistically reduction in the recurrence of hypertensive states of pregnancy (EHE), serious pre-eclampsia and minor for the gestational age (PEG) in those women who receive treatment with heparin during the pregnancy oppose to others who did not receive.
Conclusion: In spite of the fact that there seems to exist a decrease of recurrence of complications caused by the placenta such as EHE and PEG with the use of heparin, it is important to explain that in every clinical test included in our review, both the obstetric precedents, and the intervention, as well as the evaluated results are far between them for what the interpretation of the results must be done warily.
REFERENCES
Servicio de Medicina Maternofetal, Instituto Clínico de Ginecología, Obstetricia y Neonatología, Hospital Clínico de Barcelona. Hipertensión y gestación. Disponible en: https://medicinafetalbarcelona.org/clinica/images/protocolos/ patologia_materna_obstetrica/hipertensi%F3n%20 y%20gestaci%F3n.pdf. Actualizado en 2013
Lausman A, Kingdom J, Gagnon R, Basso M, Bos H, Crane J, Davies G, Delisle MF, Hudon L, Menticoglou S, Mundle W, Ouellet A, Pressey T, Pylypjuk C, Roggensack A, Sanderson F. Intrauterine growth restriction: sreeening, diagnosis, and management. Journal of Obstetrics and Gynaecology Canada. 2013; 35, 741-757
Rodger MA, Betancourt MT, Clark P, Lindqvist PG, Dizon- Townson D, Said J, Seligsohn U, Carrier M, Salomon O, Greer IA. The associatrion of factor V leiden and prothrombin gene mutation and placetna-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PloS Medicine. 2010; 7, e1000292
Urrútia G, Bonfill X. Declaración Prisma: Una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis. Medicina Clínica. 2010. 135(11), 507-511. http://www.elsevier.es/es-revista-medicina-clinica-2-articulo- declaracion prisma-una-propuesta-mejorar-S0025 775310001454?redirectNew=true
Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Mortin F, Demers C, Kahn SR, Magee LA, Rodger M. Dalteparin for the prevention of recurrence of placental mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. Journal of Thrombosis and Haemostasis. 2009. 7, 58-64
Gris JC, Chauleur C, Faillie JL, Baer G, Mares P, Fabbro-Peray P, Quere I, Lefrant JY, Haddad B, Dauzat M. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thombosis and Haemostasis. 2010. 104, 771-779
Gris JC, Chauleur, C, Molinari N, Mares P, Fabbro-Peray P, Quere I, Lefrant JY, Haddad B, Dauzat M. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thrombosis and Haemostasis. 2011. 106, 1053-1061
Martinelli I, Ruggenenti P, Cetin I, Pardi G, Perna A, Vergani P, Acaia B, Facchinetti F, La Sala GB, Bozzo M, Rampello S, Marozio L, Diadei O, Gherardi G, Carminati S, Remuzzi G, Mannucci PM. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood. 2012. 119, 3269-3275
Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, Clement AM, Coat S, Chan WS, Said F, Rey E, Robinson S, Khurana R, Demers C, Kovacs MJ, Solymoss S, Hinshaw K, Dwyer J, Smith G, McDonald S, Newstead- Angel J, McLeod A, Khandelwal M, Silver RM, Le Gal G, Greer IA, Keely E, Rosene-Montella K, Walker M, Wells PS; TIPPS Investigators. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with trombophilia (TIPPS): a multinational open-label randomised trial. The Lancet. 2014. 384(9955): 1673-1683